Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
In a separate Phase 2 type-2-diabetes trial, retatrutide lowered HbA1c by up to 2.02 points and cut body weight by about 16.9% at 36 weeks outperforming the GLP-1 agonist dulaglutide[2]
6 Summary and future perspectives Metformin, traditionally a first-line therapy for type 2 diabetes, is increasingly recognized as a pleiotropic cardiometabolic agent
VANQUISH-1 and VANQUISH-2 Obesity Trials Fully Enrolled
Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model
It continues to be investigated in diverse areas such as acute respiratory distress syndrome, toxicology, AIDS, aging, oncology, and liver disease
US$ 21.09
US$ 23.29
US$ 28.20
US$ 20.64
US$ 22.98
US$ 26.61
US$ 27.33
US$ 28.54
US$ 27.63
